Latest news

• NICE gives Bayer's Elyea a provisional 'no' for first-line use

  Lilly says that, although 2011 and 2013 NICE guidance backs laser photocoagulation as a first-line treatment of visual impairment due to BRVO, clinical practice has since changed. ... NICE's next appraisal committee meeting on Eylea  and its use in

• Bayer's Eylea cleared for wider use in Europe

  macular oedema following branch retinal vein occlusion (BRVO), while more than 50% of patients in the Eylea arm gained at least three lines of vision. ... BRVO is a common cause of visual impairment in the elderly and is around three times more common

• Germany's IQWiG delivers bad news for Bayer’s Eylea

  Bayer has also filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion (BRVO), a leading cause

• Bayer files eye drug Eylea for new use in EU

  retinal vein occlusion (BRVO), a common cause of visual impairment in the elderly. ... BRVO is around three times more common than CRVO so could provide a further fillip to growth momentum if approved.

• NICE backs new use for Bayer’s Eylea

  Lucentis has a slightly expanded indication, which also covers branch retinal vein occlusion (BRVO), although only if treatment involving the use of lasers to seal blood vessels in the eye has